Forbes April 26, 2024
In my neurotech travels the most common companies I encounter are those building digital dementia screening tools. These are a class of brain health assessments to see whether a person might have, or be at risk of developing, cognitive impairments that could be signs of neurodegenerative disease.
The number of people with Alzheimer’s disease is on pace to triple by 2060, as per CDC estimates. How best to treat them remains an open question, one that hinges on a more immediate question: Who are we treating?
Improving our ability to find people living with cognitive impairment entails identifying what disease they have, earlier in the disease’s progression. But doing this in a cost-effective, patient-centered, physician-friendly manner represents a key priority...
Today's Sponsors
Today's Sponsor